Will Going Private Jeopardize Simcere’s Status As A Partner Of Choice For Big Pharma?
This article was originally published in The Pink Sheet Daily
Executive Summary
Among U.S-listed Chinese pharmaceutical companies, Simcere has been ahead of the curve in snatching up deals with multinationals. As the Nanjing-based company gets closer to going private, could that status be a concern for potential suitors?